Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

VANFLYTA 26,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/VANFLYTA 26,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

VANFLYTA 26,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Daiichi Sankyo Europe Gmbh🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 19, 2024
Approval ID: ef2f6c9fba643f7b
Company: Daiichi Sankyo Europe Gmbh
Type: Standard

Approval Details

Approval Id: ef2f6c9fba643f7b
Drug Cima Aemps Name: VANFLYTA 26,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 1231768005
Holder Company Name: Daiichi Sankyo Europe Gmbh
Marketing Company Name: Daiichi Sankyo Espana S.A.
Holder Company Detail Path: /organization/daiichi-sankyo-europe-gmbh
Authorization Date: 2024-03-19
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 26,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Daiichi Sankyo Europe Gmbh
Company Detail Path: /organization/daiichi-sankyo-europe-gmbh

Company Information

Pharmaceutical Company Name: Daiichi Sankyo Europe GmbH
Country Name: Germany
City Name: münchen,bayern,country_de
Address: Zielstattstr. 48
Website: http://www.daiichi-sankyo.eu

Active Ingredients

QUIZARTINIB DIHIDROCLORURO

26,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 19, 2024

Approval ID

ef2f6c9fba643f7b

Type

Standard

Back to CIMA-AEMPS Approvals